<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03339817</url>
  </required_header>
  <id_info>
    <org_study_id>C16-111</org_study_id>
    <secondary_id>2017-A01845-48</secondary_id>
    <nct_id>NCT03339817</nct_id>
  </id_info>
  <brief_title>Description Des Troubles Respiratoires Chez Les Patients Suivis Pour Une Sclérose en Plaques (SEP) sévère</brief_title>
  <acronym>RespiMuS</acronym>
  <official_title>Description Des Troubles Respiratoires Chez Les Patients Suivis Pour Une Sclérose en Plaques (SEP) sévère</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to describe respiratory disorders in patients with severe
      multiple sclerosis (EDSS from 6.5).
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">January 11, 2018</start_date>
  <completion_date type="Anticipated">January 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Polysomnography</measure>
    <time_frame>Baseline only_during one night</time_frame>
    <description>presence of phasic activation of respiratory muscles</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory function testing</measure>
    <time_frame>Baseline only</time_frame>
    <description>difference between vital capacity upright and supine position (liter)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory function testing</measure>
    <time_frame>Baseline only</time_frame>
    <description>maximal inspiratory pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory function testing</measure>
    <time_frame>Baseline only</time_frame>
    <description>maximal expiratory pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory function testing</measure>
    <time_frame>Baseline only</time_frame>
    <description>SNIP (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory function testing</measure>
    <time_frame>Baseline only</time_frame>
    <description>peak flow (liter)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral and cervical spine MRI</measure>
    <time_frame>Baseline only</time_frame>
    <description>cerebral : 3DT1MPRAGE, T2 FLAIR, DWI / spine: 3DT1MPRAGE, axial T2 MEDIC, T2-WSPACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Expanded Disability Status Scale (EDSS)</measure>
    <time_frame>Baseline only</time_frame>
    <description>Neurological assessment of disability related to multiple sclerosis, total score from 0 to 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BICAMS</measure>
    <time_frame>Baseline only</time_frame>
    <description>Brief International Assessment for Multiple Sclerosis</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Respiration Disorders</condition>
  <arm_group>
    <arm_group_label>Patients with severe MS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>polysomnography and functional pulmonary testings.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Polysomnography</intervention_name>
    <description>During polysomnographia and functional pulmonary testing, signs of diaphragmatic dysfunction responsible for respiratory disorders will be searched.</description>
    <arm_group_label>Patients with severe MS</arm_group_label>
    <other_name>functional pulmonary testings</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis criteria of multiple sclerosis (MS) fulfilling revised McDonald criteria
             (2010)

          -  EDSS score from 6.5

          -  no relapse during the 3 last months

          -  Informed consent prior to any study procedure

        Exclusion Criteria:

          -  Any severe Chronic Obstructive Pulmonary Disease (III or IV)

          -  Pregnancy or woman with childbearing potential

          -  contraindication to MRI
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maillart Elisabeth, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital de la Pitié Salpétrière</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maillart Elisabeth, MD</last_name>
    <phone>01 42 16 19 75</phone>
    <email>elisabeth.maillart@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Département de Neurologie-Groupe Hospitalier Pitié-Salpêtrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth Maillart, PI</last_name>
      <phone>01 42 16 19 75</phone>
      <email>elisabeth.maillart@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>October 31, 2017</study_first_submitted>
  <study_first_submitted_qc>November 7, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <last_update_submitted>June 21, 2018</last_update_submitted>
  <last_update_submitted_qc>June 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">June 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiration Disorders</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

